Low serum albumin levels and high neutrophil counts are predictive of a poorer prognosis in patients with metastatic breast cancer

Breast cancer is a severe disease with high incidence and mortality rates in menopausal women. Previous studies have shown that nutritional status and inflammation play a significant role in the development of breast cancer. However, whether serum albumin (ALB) and neutrophils (NE) accelerate the progression of this disease remains unclear. In the present study, a total of 94 cases of newly diagnosed metastatic breast cancer were assessed. For analysis, 26 risk factors including ALB and NE were assessed. Multivariate Cox proportional hazards regression analysis was then used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) after adjusting for continuous and categorical covariates. Compared with the control group, patients with disease progression, low levels of ALB, higher NE, counts, and higher neutrophil to lymphocyte ratio counts were associated with worse overall survival (OS). When these risk factors were fitted into a multivariate regression model, progression [P<0.001, HR=3.03 (1.62-5.66)], NE counts ≥3.370×109 [P=0.004, HR=2.15 (1.27-3.65)] and ALB levels <43.275 g/l [P=0.008, HR=0.47 (0.27-0.82)] remained statistically significant factors for a worse OS. These independently associated risk factors were used to form an OS estimation nomogram. The constructed nomogram demonstrated good accuracy in estimating risk, with a bootstrap-corrected C index of 0.686. We further collected data on 30 patients for external validation and found the nomogram had an accuracy of 83.3%. In conclusion, low serum ALB levels and increased NE counts were predictive of a poorer prognosis in patients with metastatic breast cancer. Nomograms based on the multivariate analysis showed a good predictive ability for estimating the risk of OS.

[1]  Luan Xue,et al.  The potential value of fibrinogen to albumin ratio (FAR) in the assessment of inflammation in spondyloarthritis , 2022, BMC Musculoskeletal Disorders.

[2]  Stewart G. Martin,et al.  In vitro radiosensitization of breast cancer with hypoxia‐activated prodrugs , 2022, Journal of cellular and molecular medicine.

[3]  B. Czerniecki,et al.  Effect of Microporous Polysaccharide Particles in Patients Undergoing Mastectomy. , 2022, Clinical breast cancer.

[4]  J. Morote,et al.  Definition of Castrate Resistant Prostate Cancer: New Insights , 2022, Biomedicines.

[5]  N. Normanno,et al.  Lurbinectedin for small cell lung cancer , 2021, Frontiers in Oncology.

[6]  Sarah A. Frye,et al.  SNMMI Clinical Trials Network Research Series for Technologists: Ethical Issues and Regulations in the Medical Workplace , 2021, Journal of Nuclear Medicine Technology.

[7]  Zechang Xin,et al.  Development and validation of a nomogram to predict drainage duration in patients with breast cancer treated with modified radical mastectomy , 2021, Scientific Reports.

[8]  Takanobu Yamada,et al.  The Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Advanced Gastric Cancer , 2020, AntiCancer Research.

[9]  C. González-Espinosa,et al.  Mast Cells Localize in Hypoxic Zones of Tumors and Secrete CCL-2 under Hypoxia through Activation of L-Type Calcium Channels , 2020, The Journal of Immunology.

[10]  B. Han,et al.  Retracted Article: Overexpression of circ_0034642 contributes to hypoxia-induced glycolysis, cell proliferation, migration and invasion in gliomas by facilitating TAGLN2 expression via sponging miR-625-5p , 2020, RSC advances.

[11]  Yi-Shan Chen,et al.  In-depth mining of clinical data: the construction of clinical prediction model with R. , 2019, Annals of translational medicine.

[12]  Hanjoe Kim Propensity Score Analysis in Non-Randomized Experimental Designs: An Overview and a Tutorial Using R Software. , 2019, New directions for child and adolescent development.

[13]  Zhuxian Zhou,et al.  Drug-binding albumins forming stabilized nanoparticles for efficient anticancer therapy. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[14]  M. Calero,et al.  Multifunctional Albumin-Stabilized Gold Nanoclusters for the Reduction of Cancer Stem Cells , 2019, Cancers.

[15]  M. Karin,et al.  The Fire within: Cell-Autonomous Mechanisms in Inflammation-Driven Cancer. , 2019, Cancer cell.

[16]  Vanessa M. Hubbard-Lucey,et al.  Immunotherapy and targeted therapy combinations in metastatic breast cancer. , 2019, The Lancet. Oncology.

[17]  J. Xie,et al.  Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation , 2019, BioMedical Engineering OnLine.

[18]  [A consensus statement on the breast-conserving surgery of early-stage breast cancer (2019)]. , 2019, Zhonghua wai ke za zhi [Chinese journal of surgery].

[19]  H. L. Wright,et al.  Neutrophils and redox stress in the pathogenesis of autoimmune disease. , 2018, Free radical biology & medicine.

[20]  C. Duvall,et al.  Harnessing albumin as a carrier for cancer therapies , 2018, Advanced drug delivery reviews.

[21]  A. Mantovani The inflammation – cancer connection , 2018, The FEBS journal.

[22]  P. Lin,et al.  Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. , 2017, Seminars in cancer biology.

[23]  Craig L Duvall,et al.  Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing , 2017, Proceedings of the National Academy of Sciences.

[24]  K. Endo,et al.  C-Reactive Protein/Albumin Ratio and Prognostic Nutritional Index Are Strong Prognostic Indicators of Survival in Resected Pancreatic Ductal Adenocarcinoma , 2017, Journal of pancreatic cancer.

[25]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[26]  M. Levy,et al.  Role of albumin in diseases associated with severe systemic inflammation: Pathophysiologic and clinical evidence in sepsis and in decompensated cirrhosis. , 2016, Journal of critical care.

[27]  Xiaoyuan Chen,et al.  Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. , 2016, Chemical Society reviews.

[28]  Jie Chen,et al.  Low pretreatment serum globulin may predict favorable prognosis for gastric cancer patients , 2016, Tumor Biology.

[29]  Tiehong Zhang,et al.  Albumin and Neutrophil Combined Prognostic Grade as a New Prognostic Factor in Non-Small Cell Lung Cancer: Results from a Large Consecutive Cohort , 2015, PloS one.

[30]  T. Finucane,et al.  Serum Albumin and Prealbumin in Calorically Restricted, Nondiseased Individuals: A Systematic Review. , 2015, The American journal of medicine.

[31]  J. Gu,et al.  Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. , 2015, Carcinogenesis.

[32]  Zuyao Yang,et al.  Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer. , 2014, The Cochrane database of systematic reviews.

[33]  Xingsheng Wang,et al.  Changes of serum albumin level and systemic inflammatory response in inoperable non-small cell lung cancer patients after chemotherapy. , 2014, Journal of cancer research and therapeutics.

[34]  M. P. Cohen Clinical, pathophysiological and structure/function consequences of modification of albumin by Amadori-glucose adducts. , 2013, Biochimica et biophysica acta.

[35]  S. Lang,et al.  Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression. , 2013, Seminars in cancer biology.

[36]  M. Radic,et al.  Neutrophil Extracellular Traps: Double-Edged Swords of Innate Immunity , 2012, The Journal of Immunology.

[37]  T. Whiteside,et al.  Tumor‐derived macrophage migration inhibitory factor modulates the biology of head and neck cancer cells via neutrophil activation , 2011, International journal of cancer.

[38]  A. Mantovani The yin-yang of tumor-associated neutrophils. , 2009, Cancer cell.

[39]  Patrick Soon-Shiong,et al.  Protein nanoparticles as drug carriers in clinical medicine. , 2008, Advanced drug delivery reviews.

[40]  J. Grutsch,et al.  Is serum albumin an independent predictor of survival in patients with breast cancer? , 2003, JPEN. Journal of parenteral and enteral nutrition.

[41]  G. Lyman,et al.  Colony stimulating factors for chemotherapy induced febrile neutropenia. , 2003, The Cochrane database of systematic reviews.

[42]  A. Wunder,et al.  Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia. , 1997, Critical reviews in oncology/hematology.

[43]  R. Coates,et al.  Race, nutritional status, and survival from breast cancer. , 1990, Journal of the National Cancer Institute.

[44]  F. Bozzetti,et al.  Impact of Cancer, Type, Site, Stage and Treatment on the Nutritional Status of Patients , 1982, Annals of surgery.

[45]  S. Parlee,et al.  This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 International License , 2022 .